Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.36 |
| ▸ | ESR1 | P03372 | 3/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822298 | 1.00 | KMT2A (0.39) | KMT2ACYP11B2CYP11B1ESR1ESR2 | |
| SCHEMBL1825179 | 0.88 | GAA (0.38) | CYP11B2CYP11B1ESR1ESR2GAA | |
| SCHEMBL1825181 | 0.88 | GAA (0.38) | CYP11B2CYP11B1ESR1ESR2GAA | |
| SCHEMBL14191690 | 0.86 | GAA (0.44) | KMT2AGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4014545 | 0.86 | GAA (0.44) | KMT2AGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4014542 | 0.86 | GAA (0.44) | KMT2AGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1823296 | 0.82 | XDH (0.39) | CYP11B2CYP11B1MAPTALDH1A1 | |
| SCHEMBL1823294 | 0.82 | XDH (0.39) | CYP11B2CYP11B1MAPTALDH1A1 | |
| SCHEMBL1825369 | 0.80 | CYP11B1 (0.41) | CYP11B2CYP11B1GAAALDH1A1 | |
| SCHEMBL1825370 | 0.80 | CYP11B1 (0.41) | CYP11B2CYP11B1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981876-B1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| EP-1981876-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007080401-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | SLC28A1, TPMT, ACE | KMT2A 3712/4885CYP11B2 1250/4885CYP11B1 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.